



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/523,121	01/24/2005	Stanley George Bonney	PG4885USw	8414
23347	7590	12/21/2007		
GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B475 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398			EXAMINER DIXON, ANNETTE FREDRICKA	
			ART UNIT 3771	PAPER NUMBER
			NOTIFICATION DATE 12/21/2007	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USCIPRTP@GSK.COM
ROSALIE.M.CHAMBERLAIN@GSK.COM
JULIE.D.MCFALLS@GSK.COM

Office Action Summary

Application No.

10/523,121

Applicant(s)

BONNEY ET AL.

Examiner

Annette F. Dixon

Art Unit

3771

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7 and 9-37 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 9-37 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 02 October 2007 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 10/2/07.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____.

Art Unit: 3771

DETAILED ACTION

1. This Office Action is in response to the amendment filed on October 2, 2007.

Examiner acknowledges claims 1-7 and 9-37 are pending in this application with claim 1 having been currently amended, and claim 8 having been cancelled.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-7, 9, 10, 23, and 37 are rejected under 35 U.S.C. 102(b) as being anticipated by Cox et al. (6,234,167).

As to Claim 1-4, 23, and 37, Cox discloses a medicament dispenser device (121) for use in the delivery of a multi-component combination medicament product, the device comprising: a first medicament container (37) containing a plural co-formulation compatible medicament components; a first release means for the contents first medicament container for delivery thereof (35); at least one further medicament container (137), each containing at least one co-formulation incompatible medicament component; and at least one further release means for releasing the contents of each at least one further medicament container for delivery thereof (135), wherein the at least one co-formulation incompatible medicament component is kept separate from the

Art Unit: 3771

plural co-formulation compatible components until the point of release thereof for delivery in combination. Regarding the co-formulation limitation, Cox discloses the medicament containers may include two or more components mixed together before the material is volatilized. (Column 9, Lines 52-66 and Figure 3).

As to Claim 5 and 10, Cox discloses an aerosol generator (121) is an inhaler device. (Column 3, Lines 45-60).

As to Claim 6, Cox discloses the first medicament container and the second medicament container may be similar or different. Specifically, Cox discloses the first and second medicament container may be held at the same or different pressures to facilitate the delivery of the medicament to the patient. Thus inherently, the first medicament container may be similar to the second medicament container when the co-formulations are held at the same pressure or the first medicament container may be different from the second medicament container when the co-formulations are held at different pressures. (Column 8, Line 47 thru Column 9, Line 12).

As to Claim 9, Cox discloses a mixing chamber (29) including a first inlet (the location between the release means 35 and element 29) for receiving the released contents of the first medicament container (37), a second inlet (the location between the release means 135 and element 29) for receiving the released contents of the second medicament container (137), and an outlet (the location between element 29 and mouthpiece 53) for the delivery of combination medicament product therefrom.

Art Unit: 3771

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

6. Claims 11-22, and 24-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cox et al. (6,234,167) in view Marfat et al. (6,559,168).

As to Claims 11-22, and 24-36, Cox discloses a medicament device, yet does not expressly disclose the recited medicaments. However at the time the invention was made the use of the recited medicaments was well known. Specifically, Marfat discloses all the recited medicaments are known and used in the treatment of respiratory diseases such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease. (Column 209-256). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Cox to include the medicaments, as taught by Marfat, to be used in the treatment of respiratory diseases.

Response to Arguments

7. Applicant's arguments filed October 2, 2007 have been fully considered but they are not persuasive. Applicant asserts the prior art made of record does not teach or fairly suggest a first and second release means that are coupled together. Examiner respectfully disagrees with Applicant's assertion. As seen in Figure 3, the first and second release means (valves 35 and 135) are fluidly connected to each other; thereby being coupled together. Furthermore, Column 8, Lines 64-66 of the prior art teaches the valves can be opened and closed at different times. Inherently, the operation of the valves to be opened and closed at different times suggest the ability of device of Cox to have operatively coupled valves that are can operate during multiple phases independent of each other. Though Applicant asserts this understanding of the Cox device is not anticipated, Applicant has not provided a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In light of the aforementioned reasoning, the rejection of the claims has been maintained.

Conclusion

8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Samiotes (6,125,844) and Fugelsang et al. (6,523,536 and 6,698,422).

Art Unit: 3771

9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Annette F. Dixon whose telephone number is (571) 272-3392. The examiner can normally be reached on Monday thru Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Justine Yu can be reached on (571) 272-4835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3771

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Annette F Dixon
Examiner
Art Unit 3771



JUSTINE R. YU
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700

12/18/07